title: Hepatitis C virus and vaccine development.
abstract: The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine.
authors: Department of Microbiology, Qom branch, Islamic Azad University, Qom 37185-364, Iran .
authors: Malihe
authors: M
authors: Naderi
authors: National Institute of Genetic Engineering and Biotechnology, Department of Molecular Genetics, Tehran, Iran .
authors: Naghmeh
authors: N
authors: Gholipour
authors: Department of Microbiology, Qom branch, Islamic Azad University, Qom 37185-364, Iran .
authors: Mohammad Reza
authors: MR
authors: Zolfaghari
authors: Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran.
authors: Maryam
authors: M
authors: Moradi Binabaj
authors: Department of Otolaryngology, Kashan University of Medical Sciences, Kashan, Iran.
authors: Ahmad
authors: A
authors: Yegane Moghadam
authors: Department of Biology, Faculty of Science, University of Zabol, Zabol, Iran.
authors: Gholamreza
authors: G
authors: Motalleb
keywords: DNA vaccine; HCV; IFN- α; cellular immune response
references: Clin Liver Dis. 2001 Nov;5(4):931-53
references: 11685802
references: Nature. 2005 Aug 18;436(7053):961-6
references: 16107836
references: Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15394-9
references: 8986822
references: Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30
references: 17392433
references: Virol Sin. 2013 Jun;28(3):167-73
references: 23709057
references: J Virol. 2002 Sep;76(18):9335-44
references: 12186916
references: J Virol. 1997 May;71(5):3767-75
references: 9094652
references: J Virol. 1994 Jun;68(6):3631-41
references: 8189501
references: Proc Natl Acad Sci U S A. 1990 Dec;87(24):9524-8
references: 2175903
references: J Natl Cancer Inst. 1999 Jun 2;91(11):906-8
references: 10359539
references: Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9716-23
references: 8790397
references: JAMA. 2003 Jul 9;290(2):228-37
references: 12851278
references: J Biosci. 2003 Apr;28(3):287-304
references: 12734407
references: FASEB J. 1997 Aug;11(10):753-63
references: 9271360
references: Vaccine. 2008 Nov 18;26(49):6225-31
references: 18692108
references: Virology. 1996 Aug 1;222(1):51-63
references: 8806487
references: Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8239-43
references: 8058787
references: Proc Natl Acad Sci U S A. 1990 Mar;87(6):2057-61
references: 2156259
references: J Hepatol. 2002 Feb;36(2):254-62
references: 11830338
references: J Virol. 1997 Apr;71(4):2838-43
references: 9060639
references: FEMS Microbiol Rev. 1994 Jul;14(3):273-7
references: 8086198
references: Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294-8
references: 7509068
references: Antiviral Res. 2009 Oct;84(1):23-30
references: 19646486
references: Science. 2003 Oct 24;302(5645):659-62
references: 14576438
references: J Gen Virol. 2005 Jul;86(Pt 7):1931-42
references: 15958671
references: J Immunol. 1999 Jan 15;162(2):931-8
references: 9916717
references: Virology. 2002 Jan 5;292(1):24-34
references: 11878905
references: J Virol. 2004 Aug;78(16):8835-43
references: 15280491
references: J Virol. 1997 Jan;71(1):697-704
references: 8985401
references: Int J Med Sci. 2006;3(2):29-34
references: 16614739
references: J Virol. 2009 Jan;83(2):1071-82
references: 18971279
references: Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5547-51
references: 1648221
references: J Biol Chem. 2007 Nov 9;282(45):32765-72
references: 17704057
references: J Virol. 2003 Oct;77(20):10862-71
references: 14512536
references: J Clin Invest. 1997 Apr 1;99(7):1472-7
references: 9119989
references: Genet Vaccines Ther. 2009 Jun 08;7:7
references: 19505299
references: Expert Rev Vaccines. 2009 Mar;8(3):333-45
references: 19249975
references: J Infect Dis. 1990 Jun;161(6):1134-9
references: 1693159
references: Biochem Biophys Res Commun. 1993 Apr 30;192(2):399-406
references: 8387277
references: Antivir Ther. 2003 Feb;8(1):57-63
references: 12713065
references: Emerg Microbes Infect. 2013 Nov;2(11):e79
references: 26038445
references: Expert Rev Vaccines. 2011 May;10(5):659-72
references: 21604986
references: J Ayub Med Coll Abbottabad. 2008 Jan-Mar;20(1):129-33
references: 19024206
references: J Exp Med. 1997 Apr 21;185(8):1505-10
references: 9126932
references: J Exp Med. 2003 Jun 16;197(12):1645-55
references: 12810686
references: Cell J. 2014 Winter;15(4):324-31
references: 24381857
references: J Virol. 1993 Jul;67(7):3835-44
references: 8389908
references: J Virol. 1993 Jun;67(6):3288-94
references: 8388499
references: Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451-5
references: 1848704
references: Curr Mol Med. 2001 May;1(2):217-43
references: 11899073
references: Iran J Cancer Prev. 2013 Spring;6(2):101-7
references: 25250118
references: Liver Transpl. 2000 Jul;6(4):396-406
references: 10915159
references: Hepatobiliary Pancreat Dis Int. 2002 May;1(2):228-31
references: 14612273
references: J Virol. 1993 May;67(5):2832-43
references: 8386278
references: Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7792-6
references: 7519785
references: Indian J Clin Biochem. 2009 Jul;24(3):234-40
references: 23105841
references: Immune Netw. 2009 Oct;9(5):169-78
references: 20157605
references: J Hepatol. 2002 Nov;37(5):684-95
references: 12399239